Join epidemiologist Nic Hulscher from the McCullough Foundation on @CDM_PRESS with Bill Quinn for a fascinating deep dive into the rising wave of aggressive “turbo cancers” hitting younger people harder than ever.
Nic breaks down how everyday antiparasitic drugs like Ivermectin and Fenbendazole—backed by Nobel Prize-winning science and tons of promising studies—are stepping up as game-changers in the fight against cancer.
From shrinking tumors in animal models to real-life stories of stage-four remissions without chemo, this conversation uncovers why these safe, affordable options could revolutionize treatment, especially amid post-vaccine cancer spikes.
Hear about the push for over-the-counter access in states like Florida, Big Pharma’s resistance, and why human trials are urgently needed.
If you’re tracking health breakthroughs or dealing with cancer concerns, this eye-opener packs hope, facts, and a call to action you won’t want to miss.
0:00: Introduction to Nic Hulscher and the rising cancer epidemic
1:21: Hulscher’s background and McCullough Foundation’s research on turbo cancers
2:45: Promise of antiparasitics in pre-clinical studies against cancer
3:22: Ivermectin’s efficacy in studies and combination with Fenbendazole
4:50: Mechanisms of Ivermectin in killing cancer cells across 12 types
5:59: Safety of Ivermectin with chemotherapy and remission cases
7:38: History of Ivermectin, Nobel Prize, and superior safety profile
9:12: State efforts to make Ivermectin over-the-counter for public access
13:19: Fenbendazole’s success in stage 4 cancer remissions without chemo
17:15: Nano-Ivermectin shrinking glioblastoma tumors by 70% in animal models
